Skip to Content
Merck
  • Iron oxide nanoparticle-mediated development of cellular gap junction crosstalk to improve mesenchymal stem cells' therapeutic efficacy for myocardial infarction.

Iron oxide nanoparticle-mediated development of cellular gap junction crosstalk to improve mesenchymal stem cells' therapeutic efficacy for myocardial infarction.

ACS nano (2015-02-18)
Jin Han, Bokyoung Kim, Jung-Youn Shin, Seungmi Ryu, Myungkyung Noh, Jongsu Woo, Jin-Sil Park, Youjin Lee, Nohyun Lee, Taeghwan Hyeon, Donghoon Choi, Byung-Soo Kim
ABSTRACT

Electrophysiological phenotype development and paracrine action of mesenchymal stem cells (MSCs) are the critical factors that determine the therapeutic efficacy of MSCs for myocardial infarction (MI). In such respect, coculture of MSCs with cardiac cells has windowed a platform for cardiac priming of MSCs. Particularly, active gap junctional crosstalk of MSCs with cardiac cells in coculture has been known to play a major role in the MSC modification through coculture. Here, we report that iron oxide nanoparticles (IONPs) significantly augment the expression of connexin 43 (Cx43), a gap junction protein, of cardiomyoblasts (H9C2), which would be critical for gap junctional communication with MSCs in coculture for the generation of therapeutic potential-improved MSCs. MSCs cocultured with IONP-harboring H9C2 (cocultured MSCs: cMSCs) showed active cellular crosstalk with H9C2 and displayed significantly higher levels of electrophysiological cardiac biomarkers and a cardiac repair-favorable paracrine profile, both of which are responsible for MI repair. Accordingly, significantly improved animal survival and heart function were observed upon cMSC injection into rat MI models compared with the injection of unmodified MSCs. The present study highlights an application of IONPs in developing gap junctional crosstalk among the cells and generating cMSCs that exceeds the reparative potentials of conventional MSCs. On the basis of our finding, the potential application of IONPs can be extended in cell biology and stem cell-based therapies.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Titanium tetrachloride, packaged for use in deposition systems
Supelco
Rhodamine B, analytical standard
Sigma-Aldrich
Rhodamine B, for fluorescence
Sigma-Aldrich
Calcein-AM, Small Package (20 X 50 μg ), ≥95.0% (HPLC)
Supelco
Rhodamine B solution, 0.2% in isopropanol, for TLC derivatization
Sigma-Aldrich
Rhodamine B, Dye content 90 %
Sigma-Aldrich
Rhodamine B, ≥95% (HPLC)
Sigma-Aldrich
Titanium(IV) chloride solution, 1.0 M in methylene chloride
Lysine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Titanium(IV) chloride solution, 0.09 M in 20% HCl
Sigma-Aldrich
Calcein-AM, suitable for fluorescence, BioReagent, ≥90% (HPLC)
Supelco
L-Lysine monohydrochloride, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
L-Lysine monohydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Oleic acid, natural, FCC
Sigma-Aldrich
Benzyl ether, ≥98%, FCC, FG
Supelco
Oleic acid, analytical standard
Sigma-Aldrich
Oleic acid, technical grade, 90%
Sigma-Aldrich
Calcein AM solution, 4 mM in DMSO, ≥90% (HPLC), solution
Sigma-Aldrich
L-Lysine monohydrochloride, BioUltra, ≥99.5% (AT)
Supelco
L-Lysine hydrochloride solution, 100 mM amino acid in 0.1 M HCl, analytical standard
Sigma-Aldrich
L-Lysine monohydrochloride, reagent grade, ≥98% (HPLC)
Sigma-Aldrich
Oleic acid, BioReagent, suitable for cell culture
Sigma-Aldrich
Oleic acid, ≥99% (GC)
Sigma-Aldrich
L-Lysine monohydrochloride, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Supelco
Oleic acid, Selectophore, ≥99%
Oleic acid, European Pharmacopoeia (EP) Reference Standard
Tribenoside impurity D, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Titanium(IV) chloride, ReagentPlus®, 99.9% trace metals basis
Sigma-Aldrich
Dibenzyl ether, purum, ≥98.0% (GC)
Sigma-Aldrich
Benzyl ether, 98%